2Million2Many campaign flags bone fracture, osteoporosis link

Share this article:
2Million2Many campaign flags bone fracture, osteoporosis link
2Million2Many campaign flags bone fracture, osteoporosis link
The National Bone Health Alliance and inVentiv shop GSW Worldwide are launching 2Million2Many, a national education campaign designed to raise awareness of the connection between osteoporosis and broken bones.

The campaign, including print ads, a microsite (2million2many.org), PSA and documentary, will urge Americans 50 and up to get follow-up testing when they break a bone.

“Every year, there are two million broken bones caused by osteoporosis, and yet only two in ten get a follow-up test or treatment for osteoporosis,” said GSW Worldwide's Marcee Nelson. “We need to help people visualize this impact, and to make it relevant to them now, while they can still do something to prevent it.”

As a visual aid, the effort features Cast Mountain, a 2,500-pound assemblage of fiberglass casts and resin representing the 5,500 broken bones that happen each day, the agency said. The sculpture will go on tour starting at this week's International Symposium on Osteoporosis in Orlando, FL.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...